刘谋泽, 何发忠, 张伟. 抗肿瘤药物的表观遗传学研究进展J. 药学学报, 2013,48(11): 1629-1636.
引用本文: 刘谋泽, 何发忠, 张伟. 抗肿瘤药物的表观遗传学研究进展J. 药学学报, 2013,48(11): 1629-1636.
LIU Mou-ze, HE Fa-zhong, ZHANG Wei. Epigenetic research progress of anti-tumor drugsJ. Acta Pharmaceutica Sinica, 2013,48(11): 1629-1636.
Citation: LIU Mou-ze, HE Fa-zhong, ZHANG Wei. Epigenetic research progress of anti-tumor drugsJ. Acta Pharmaceutica Sinica, 2013,48(11): 1629-1636.

抗肿瘤药物的表观遗传学研究进展

Epigenetic research progress of anti-tumor drugs

  • 摘要: 表观遗传学异常不仅与某些癌症发病相关, 还可能通过修饰药物吸收、分布、代谢、排泄等药动学相关基因及信号通路、作用靶点等药效学相关基因, 而影响抗癌药物疗效和预后。通过调控表观调控因子发挥抗癌效应的药物正成为研究的热点。本文从DNA甲基化、miRNA和组蛋白修饰对抗肿瘤药物的治疗作用进行综述和分析, 旨在为抗肿瘤药物安全有效的合理使用及发展"表观药物"提供新的思路。

     

    Abstract: Epigenetic abnormalities not only associated with carcinogenesis, they may also influence the curative effect and prognosis of anticancer drugs through modifying pharmacokinetic genes related to drug absorption, distribution, metabolism, excretion and pharmacodynamic genes related to signaling pathways and targets. That drugs through regulating epigenetic factors pocessing anti-cancer effect is becoming a research hot spot. We summarized and analyzed the realtionship of DNA methylation, miRNA, and histone modification with antitumor drug effect, aiming at promoting rational use of antitumor drugs and providing new ideas on developing epi-drugs.

     

/

返回文章
返回